For most long-term smokers, the lung disease that arrives first is COPD — chronic bronchitis or emphysema, often diagnosed in the 50s or 60s after years of progressive shortness of breath. For a smaller but still substantial group, a different lung disease shows up: pulmonary fibrosis, in which the lung tissue itself stiffens and scars, gradually losing its ability to move oxygen into the bloodstream. The shortness of breath that follows is unrelenting. The disease progresses regardless of whether the patient stops smoking. The five-year survival, for the most common form — idiopathic pulmonary fibrosis (IPF) — is poorer than for most cancers.
This piece walks through what the medical literature says about the connection between smoking and pulmonary fibrosis, why these cases are sometimes missed in early conversations about tobacco litigation, and how the legal framework applies.
What Pulmonary Fibrosis Is
The lungs are made up of millions of tiny air sacs (alveoli) surrounded by thin walls of connective tissue. Oxygen moves through those walls into the bloodstream, and carbon dioxide moves out. In pulmonary fibrosis, the walls thicken and stiffen with fibrous scar tissue. The lungs become harder to expand, the surface available for gas exchange shrinks, and oxygen levels fall.
The most common form — idiopathic pulmonary fibrosis (IPF) — was called "idiopathic" historically because the cause was thought to be unknown. The more current scientific consensus is that IPF is not truly idiopathic. It is the end result of repeated injury to the alveolar epithelium in genetically and environmentally susceptible individuals. The risk factors identified in the published literature include:
- Cigarette smoking — the single strongest environmental risk factor, with substantially higher IPF risk in current and former smokers compared with never-smokers.
- Occupational exposures — metal dust, wood dust, stone dust, asbestos, silica.
- Chronic microaspiration (gastroesophageal reflux disease).
- Viral infections, including Epstein-Barr virus.
- Family history and specific genetic variants.
The American Thoracic Society, the European Respiratory Society, and the National Heart, Lung, and Blood Institute all identify smoking as a major risk factor for IPF in their published clinical guidance.
Other Smoking-Related Interstitial Lung Diseases
IPF is the most well-known smoking-related interstitial lung disease, but it is not the only one. The category of "smoking-related interstitial lung diseases" includes:
- Respiratory bronchiolitis-interstitial lung disease (RB-ILD) — almost exclusively seen in smokers.
- Desquamative interstitial pneumonia (DIP) — strongly associated with smoking.
- Pulmonary Langerhans cell histiocytosis — almost exclusively seen in smokers.
- Combined pulmonary fibrosis and emphysema (CPFE) — a distinct syndrome in heavy smokers with both fibrosis and emphysema together, recognized as a separate diagnostic entity in the pulmonology literature.
Each of these has its own diagnostic features on imaging and pathology, and each has its own treatment considerations. From a legal perspective, the common feature is that smoking is a documented contributing cause.
Why the Diagnosis Often Surprises Patients
Many smokers diagnosed with pulmonary fibrosis are told, or come to believe, that the disease is "idiopathic" and unrelated to anything they did. The implication — that there is nothing to be done legally because the cause is unknown — is not consistent with the modern medical literature. The current evidence supports a smoking link strong enough that smoking history is part of the diagnostic conversation in most pulmonology clinics. Patients and families who were told otherwise may not have heard the full picture.
A second reason the diagnosis surprises patients: pulmonary fibrosis can present years or decades after the patient stopped smoking. A person who quit at 50 and is diagnosed at 65 may not connect the disease to their earlier smoking. The medicine, however, has identified former smoking as a risk factor on its own — not just current smoking.
What the Diagnosis Looks Like
The diagnosis is typically built from:
- Clinical history — progressive shortness of breath, dry cough, fatigue, and often "Velcro" crackles heard at the lung bases on physical exam.
- High-resolution CT (HRCT) of the chest — the imaging study that identifies the pattern of fibrosis (usual interstitial pneumonia, or UIP, for IPF) and distinguishes IPF from other interstitial lung diseases.
- Pulmonary function tests — showing restrictive disease (reduced lung volumes) and impaired gas exchange (reduced diffusing capacity).
- Lung biopsy in selected cases — surgical, transbronchial, or cryobiopsy — with pathology confirming the fibrosis pattern.
- Multidisciplinary discussion (MDD) — the diagnostic standard for many interstitial lung diseases is a joint review by a pulmonologist, a radiologist, and a pathologist together.
The Legal Framework
Smoking-related pulmonary fibrosis cases proceed on the same liability framework as other smoking-disease cases against the tobacco industry. The theories generally include:
- Negligent design, manufacture, and marketing of cigarettes.
- Strict product liability for an unreasonably dangerous product.
- Failure to warn about the carcinogenic and toxic effects of cigarette smoke.
- Fraud and misrepresentation about the safety and addictiveness of the products.
- Civil conspiracy among tobacco companies to suppress health research.
The internal industry documents released through prior tobacco litigation — sometimes called the "tobacco documents" — remain a central piece of evidence. Our companion piece on how tobacco companies hid the truth walks through that record.
What Pulmonary Fibrosis Cases Need
- A documented diagnosis of pulmonary fibrosis or another smoking-related interstitial lung disease, supported by imaging and (where performed) pathology.
- Substantial smoking history (pack-years).
- Brand identification.
- Causation evidence from a pulmonology expert familiar with the smoking-pulmonary-fibrosis literature.
- Documentation of the disease's impact on the patient — oxygen dependence, hospitalizations, quality of life, treatment course.
- For cases brought after the patient's death, the cause-of-death documentation and the disease-course records.
Treatment History and Damages
Pulmonary fibrosis treatment has improved meaningfully but remains limited. The two FDA-approved antifibrotic medications — pirfenidone and nintedanib — slow the rate of lung-function decline but do not reverse fibrosis. Pulmonary rehabilitation, supplemental oxygen, treatment of comorbidities, and (in selected patients) lung transplantation are part of the management picture. The progression from "noticing shortness of breath on the stairs" to "needing oxygen at rest" to "evaluating for transplant or hospice" can compress into a few years. The damages picture in pulmonary fibrosis cases reflects that trajectory.
The Jurisdictions We Serve
The Alvarez Law Firm represents smokers and families in Nevada, Oregon, Hawaii, Illinois, the U.S. Virgin Islands, and Pennsylvania. Each of those jurisdictions has its own filing deadlines, its own substantive law on tobacco product liability, and its own procedural rules for personal injury and wrongful death actions. Deadlines vary, and the discovery rule — how long after diagnosis a case has to be filed when the smoking-disease connection was not initially apparent — varies as well. Talk to counsel licensed in the relevant state about how those rules apply to your specific situation. Waiting can foreclose options that were available earlier.
If You or a Family Member Has Pulmonary Fibrosis
If you have a substantial smoking history and have been diagnosed with idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema, or another smoking-related interstitial lung disease, a free, confidential case review is the right next step. Many families have been told the disease is "idiopathic" without learning that the modern medical literature recognizes smoking as a major risk factor. The same conversation that produces a viable lung cancer or COPD case can produce a viable pulmonary fibrosis case.
- Read about lung cancer cases: Lung Cancer Smoking Lawsuit Legal Rights.
- Read about COPD cases: COPD Smoking Legal Rights.
- Read about smoking history documentation: Smoking History Documentation.
- Read about how the industry concealed risk: How Tobacco Companies Hid the Truth.
- Read the wrongful death family guide: Smokers Wrongful Death Family Guide.
Free case review. No fees unless we recover compensation for you.
Sources
- American Thoracic Society / European Respiratory Society — "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline." thoracic.org
- National Heart, Lung, and Blood Institute — "Idiopathic Pulmonary Fibrosis." nhlbi.nih.gov
- U.S. Surgeon General — "The Health Consequences of Smoking — 50 Years of Progress" (2014 report). cdc.gov/tobacco
- Pulmonary Fibrosis Foundation — Patient and clinician resources on IPF and other interstitial lung diseases. pulmonaryfibrosis.org
- American Lung Association — Pulmonary fibrosis overview and treatment guidance. lung.org
- NIH National Library of Medicine / PMC — Peer-reviewed literature on smoking and interstitial lung disease (including combined pulmonary fibrosis and emphysema). ncbi.nlm.nih.gov/pmc